Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.71 |
| ▸ | MAOA | P21397 | 1/20 | 0.61 |
| ▸ | MAOB | P27338 | 1/20 | 0.61 |
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | CA12 | O43570 | 6/20 | 0.56 |
| ▸ | CA1 | P00915 | 6/20 | 0.56 |
| ▸ | CA2 | P00918 | 6/20 | 0.56 |
| ▸ | CA9 | Q16790 | 6/20 | 0.56 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 4/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21596987 | 1.00 | TDP1 (0.71) | TDP1MAOAMAOBMEN1KMT2A | |
| SCHEMBL6449941 | 1.00 | TDP1 (0.71) | TDP1MAOAMAOBMEN1KMT2A | |
| SCHEMBL7292779 | 1.00 | TDP1 (0.71) | TDP1MAOAMAOBMEN1KMT2A | |
| SCHEMBL17286185 | 1.00 | TDP1 (0.71) | TDP1MAOAMAOBMEN1KMT2A | |
| SCHEMBL1041731 | 1.00 | TDP1 (0.71) | TDP1MAOAMAOBMEN1KMT2A | |
| SCHEMBL1149061 | 1.00 | TDP1 (0.71) | TDP1MAOAMAOBMEN1KMT2A | |
| SCHEMBL19460948 | 1.00 | TDP1 (0.71) | TDP1MAOAMAOBMEN1KMT2A | |
| SCHEMBL26634879 | 1.00 | TDP1 (0.71) | TDP1MAOAMAOBMEN1KMT2A | |
| SCHEMBL229087 | 0.98 | TDP1 (0.68) | TDP1MAOAMAOBMEN1KMT2A | |
| SCHEMBL7434 | 0.92 | TDP1 (0.65) | TDP1MAOAMAOBMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023055952-A1 | NEUROTROPHIC TYROSINE RECEPTOR KINASE (NTRK) DEGRADING COMPOUNDS | C4 THERAPEUTICS, INC. (US) | 2023-04-06 | — | — | WO | disclosed |
| US-10994016-B2 | Graphene oxide mediated cellular delivery of gadolinium-labeled molecules | NORTHWESTERN UNIVERSITY (US) | 2021-05-04 | — | — | US | disclosed |
| US-20200362174-A1 | COMPOUNDS AND METHODS FOR OPTICAL SENSING OF ELECTRICAL ACTIVITY IN BIOLOGICAL SYSTEMS | UNIVERSITY OF CONNECTICUT | 2020-11-19 | — | — | US | disclosed |
| US-20200362174-A1 | COMPOUNDS AND METHODS FOR OPTICAL SENSING OF ELECTRICAL ACTIVITY IN BIOLOGICAL SYSTEMS | UNIVERSITY OF CONNECTICUT | 2020-11-19 | — | — | US | disclosed |
| CN-110452314-A | Anoxic sensitivity response type chitosan nitroimidazole grafting and preparation and application | UNIV ZHEJIANG | 2019-11-15 | — | — | CN | disclosed |
| US-20170074859-A1 | Graphene Oxide Cellular Delivery of Hydrophilic Small Molecules | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-03-16 | — | — | US | disclosed |
| US-20170074859-A1 | Graphene Oxide Cellular Delivery of Hydrophilic Small Molecules | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-03-16 | — | — | US | disclosed |
| US-20170074859-A1 | Graphene Oxide Cellular Delivery of Hydrophilic Small Molecules | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-03-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10994016-B2 | Graphene oxide mediated cellular delivery of gadolinium-labeled molecules | GZMB, GCG, GLMN | TDP1 4111/4885MAOA 2362/4885MAOB 1427/4885 |
| US-20170074859-A1 | Graphene Oxide Cellular Delivery of Hydrophilic Small Molecules | CD44, EPCAM, VIM | TDP1 4616/4885MAOA 2648/4885MAOB 1846/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.